All News

The Swedish Research Council has announced the formation of the first centreswhich are designed to link leading groups in basic science with industry and the public sector.

In its last issue, the Economist presents a survey on talent and the difficulties of finding and keeping it. As usual, it is an instructive and stimulating piece. In my case, it stimulated my thoughts about the relationships between talent and intellectual property (IP).

Why do so many European inventions get lost in the move from lab to market? Science|Business suggests 9 simple ways that European leaders could fix that problem – for the benefit of Europe’s economy.

The Scottish Executive is seeking input on a proposed new science and innovation strategy for Scotland.

A paper from the London School of Economics questions the EU's chances of catching up with the USA on innovation and productivity.

European companies raised their R&D spending by 5.3 per cent last year - but still failed to keep up with bigger-spending U.S. and Asian competitors in the global R&D market, data from a European Commission study suggest.

Pepsi to locate Global R&D for Next-Generation Products in Cork

The 2006 EU Industrial R&D Investment Scoreboard provides information of the top 1000 EU companies and top 1000 from outside the EU (non-EU) which invest the most in R&D.

What is white biotech? Can it save the planet?

After months of talking, Imperial College London and the University of London set terms for their separation - a major break-up among R&D heavyweights.

An obsession with the equity gap is obscuring the real reasons why universities are failing to commercialise their research, says one of the UK's leading spin-out investors.

These days, Big Pharma does not appear to have many friends. The market performance of many big pharmaceutical companies has been middling, as the sector’s competitive position is perceived to be under several threats. The drug pipeline appears to be drying up and geared more toward lifestyle enhancement than life savings. Costly and reputation-damaging liability suits are proliferating. Pricing pressures are relentless. They come from pressure groups such as AIDS patients; but they are reinforced by public authorities, not only in the developing world but also in the US and in Europe, as governments seek to slow down the relentless progress of health expenditures.